{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:06:51Z","timestamp":1792782411626,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Universit\u00e4tsklinikum Leipzig","id":[{"id":"https:\/\/ror.org\/028hv5492","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Unser Fall zeigt die wirksame kombinierte Therapie mit Ipilimumab und Nivolumab beim SS, die insbesondere in Kombination mit ECP und im Kontext der metastasierten Melanomerkrankung zu einer stabilen partiellen Remission gef\u00fchrt hat. Zu dem bef\u00fcrchteten Hyperprogress ist es nicht gekommen. Der initiale Flare konnte durch eine Therapie mit topischen Glukokortikosteroiden und kurzzeitiges Zuwarten nach dem ersten Zyklus Ipilimumab und Nivolumab gut beherrscht werden. Im l\u00e4ngeren Verlauf entwickelte der Patient ein immuntherapiebedingtes lichenoides Arzneimittelexanthem, welches letztlich zu einer Pausierung der Therapie f\u00fchrte. In Folge kam es zum erneuten zerebralen Progress des Melanoms.<\/jats:p>","DOI":"10.1007\/s00105-026-05706-1","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T07:39:42Z","timestamp":1778485182000},"page":"686-689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Erfolgreiche Checkpointinhibition plus extrakorporale Photopherese bei einem Patienten mit metastasiertem Melanom und fortgeschrittenem S\u00e9zary-Syndrom","Successful checkpoint inhibition plus extracorporeal photopheresis in patients with metastatic melanoma and advanced S\u00e9zary syndrome"],"prefix":"10.1007","volume":"77","author":[{"given":"Franziska","family":"Jochims","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjana","family":"Ziemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"5706_CR1","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/ddg.14706_g","volume":"20","author":"E Dippel","year":"2022","unstructured":"Dippel\u00a0E, Assaf\u00a0C, Becker\u00a0JC, von Bergwelt-Baildon\u00a0M, Bernreiter\u00a0S, Cozzio\u00a0A et\u00a0al (2022) S2k-Leitlinie - Kutane Lymphome (ICD 10 C82-C86): Update 2021. J\u00a0Dtsch Dermatol Ges 20:537\u2013555. https:\/\/doi.org\/10.1111\/ddg.14706_g","journal-title":"J Dtsch Dermatol Ges"},{"key":"5706_CR2","doi-asserted-by":"publisher","DOI":"10.4081\/hr.2018.7497","volume":"10","author":"H Hosoi","year":"2018","unstructured":"Hosoi\u00a0H, Hatanaka\u00a0K, Murata\u00a0S, Mushino\u00a0T, Kuriyama\u00a0K, Nishikawa\u00a0A et\u00a0al (2018) Long-term complete remission of early hematological relapse after discontinuation of immunosuppressants following allogeneic transplantation for Sezary syndrome. Hematol Rep 10:7497. https:\/\/doi.org\/10.4081\/hr.2018.7497","journal-title":"Hematol Rep"},{"key":"5706_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.733770","volume":"11","author":"G Roccuzzo","year":"2021","unstructured":"Roccuzzo\u00a0G, Giordano\u00a0S, Fava\u00a0P, Pileri\u00a0A, Guglielmo\u00a0A, Tonella\u00a0L et\u00a0al (2021) Immune Check Point Inhibitors in Primary Cutaneous T\u2011Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives. Front Oncol 11:733770. https:\/\/doi.org\/10.3389\/fonc.2021.733770","journal-title":"Front Oncol"},{"key":"5706_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jdcr.2015.02.009","volume":"1","author":"G Bar-Sela","year":"2015","unstructured":"Bar-Sela\u00a0G, Bergman\u00a0R (2015) Complete regression of mycosis fungoides after ipilimumab therapy for advanced melanoma. JAAD Case Rep 1:99\u2013100. https:\/\/doi.org\/10.1016\/j.jdcr.2015.02.009","journal-title":"JAAD Case Rep"},{"key":"5706_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1182\/blood.V128.22.183.183","volume":"128","author":"S Ansell","year":"2016","unstructured":"Ansell\u00a0S, Gutierrez\u00a0ME, Shipp\u00a0MA, Gladstone\u00a0D, Moskowitz\u00a0A, Borello\u00a0I et\u00a0al (2016) A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039). Blood 128:183\u2013183. https:\/\/doi.org\/10.1182\/blood.V128.22.183.183","journal-title":"Blood"},{"key":"5706_CR6","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1001\/jamadermatol.2025.0251","volume":"161","author":"O Elghawy","year":"2025","unstructured":"Elghawy\u00a0O, Sussman\u00a0JH, Yang\u00a0AG, Thomas\u00a0CJ, Carter\u00a0JS, Landsburg\u00a0DJ et\u00a0al (2025) Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or S\u00e9zary Syndrome. JAMA Dermatol 161:656\u2013658. https:\/\/doi.org\/10.1001\/jamadermatol.2025.0251","journal-title":"JAMA Dermatol"},{"key":"5706_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115484","volume":"222","author":"R Stadler","year":"2025","unstructured":"Stadler\u00a0R, Roccuzzo\u00a0G, Ortiz-Romero\u00a0P, Bagot\u00a0M, Quaglino\u00a0P, Guenova\u00a0E et\u00a0al (2025) Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed\/refractory IIB\/IVB mycosis fungoides\/S\u00e9zary syndrome patients after previous systemic treatment. EORTC-1652-CLTG \u201cPARCT\u201d. Eur J Cancer 222:115484. https:\/\/doi.org\/10.1016\/j.ejca.2025.115484","journal-title":"Eur J Cancer"},{"key":"5706_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/JCO.19.01056","volume":"38","author":"MS Khodadoust","year":"2020","unstructured":"Khodadoust\u00a0MS, Rook\u00a0AH, Porcu\u00a0P, Foss\u00a0F, Moskowitz\u00a0AJ, Shustov\u00a0A et\u00a0al (2020) Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and S\u00e9zary Syndrome: A Multicenter Phase II Study. J\u00a0Clin Oncol 38:20\u201328. https:\/\/doi.org\/10.1200\/JCO.19.01056","journal-title":"J Clin Oncol"},{"key":"5706_CR9","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"Lesokhin\u00a0AM, Ansell\u00a0SM, Armand\u00a0P, Scott\u00a0EC, Halwani\u00a0A, Gutierrez\u00a0M et\u00a0al (2016) Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J\u00a0Clin Oncol 34:2698\u20132704. https:\/\/doi.org\/10.1200\/JCO.2015.65.9789","journal-title":"J Clin Oncol"},{"key":"5706_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1291259","volume":"14","author":"I Quadri","year":"2023","unstructured":"Quadri\u00a0I, Reneau\u00a0JC, Hanel\u00a0W, Chung\u00a0CG (2023) Advancements in the treatment of mycosis fungoides and S\u00e9zary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors. Front Immunol 14:1291259. https:\/\/doi.org\/10.3389\/fimmu.2023.1291259","journal-title":"Front Immunol"},{"key":"5706_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.164793","author":"Y Gao","year":"2023","unstructured":"Gao\u00a0Y, Hu\u00a0S, Li\u00a0R, Jin\u00a0S, Liu\u00a0F, Liu\u00a0X et\u00a0al (2023) Hyperprogression of cutaneous T cell lymphoma after anti-PD\u20111 treatment. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.164793","journal-title":"JCI Insight"},{"key":"5706_CR12","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/bloodadvances.2020002371","volume":"5","author":"S Beygi","year":"2021","unstructured":"Beygi\u00a0S, Fernandez-Pol\u00a0S, Duran\u00a0G, Wang\u00a0EB, Stehr\u00a0H, Zehnder\u00a0JL et\u00a0al (2021) Pembrolizumab in mycosis fungoides with PD-L1 structural variants. Blood Adv 5:771\u2013774. https:\/\/doi.org\/10.1182\/bloodadvances.2020002371","journal-title":"Blood Adv"},{"key":"5706_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2115197","volume":"11","author":"T Su","year":"2022","unstructured":"Su\u00a0T, Duran\u00a0GE, Kwang\u00a0AC, Ramchurren\u00a0N, Fling\u00a0SP, Kim\u00a0YH, Khodadoust\u00a0MS (2022) Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in S\u00e9zary syndrome. Oncoimmunology 11:2115197. https:\/\/doi.org\/10.1080\/2162402X.2022.2115197","journal-title":"Oncoimmunology"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05706-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05706-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05706-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:52:57Z","timestamp":1790855577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05706-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5706"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05706-1","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.\u00a0Jochims und M.\u00a0Ziemer geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}